WOOJUNG BIO, Inc.

Equities

A215380

KR7215380007

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-02 pm EDT			5-day change	1st Jan Change
1,658 ^KRW	-0.42%		+1.28%	-20.67%

2023	WOOJUNG BIO, Inc. announced that it has received KRW 5 billion in funding from Korea Investment Partners Co. Ltd.	CI
2023	WOOJUNG BIO, Inc. announced that it expects to receive KRW 5 billion in funding from Korea Investment Partners Co. Ltd.	CI

Focus Asset Management acquired 4.4% stake in Hanwha MGI Special Purpose Acquisition Co., Ltd..

April 24, 2017

Focus Asset Management acquired 4.4% stake in Hanwha MGI Special Purpose Acquisition Co., Ltd. (KOSDAQ:A215380) on April 25, 2017. Focus Asset Management completed the acquisition of 4.4% stake in Hanwha MGI Special Purpose Acquisition Co., Ltd. (KOSDAQ:A215380) on April 25, 2017.

Latest news about WOOJUNG BIO, Inc.

WOOJUNG BIO, Inc. announced that it has received KRW 5 billion in funding from Korea Investment Partners Co. Ltd.	23-05-30	CI
WOOJUNG BIO, Inc. announced that it expects to receive KRW 5 billion in funding from Korea Investment Partners Co. Ltd.	23-05-24	CI
WOOJUNG BIO, Inc. announced that it has received KRW 8.999979915 billion in funding from Mercury Asset Management Co., Ltd., Ryan Asset Management Co., Ltd., Timefolio Asset Management Co.,Ltd	22-05-24	CI
WOOJUNG BIO, Inc. announced that it expects to receive KRW 8.999979915 billion in funding from Mercury Asset Management Co., Ltd., Ryan Asset Management Co., Ltd., Timefolio Asset Management Co.,Ltd	22-05-16	CI
WOOJUNG BIO, Inc. announced that it expects to receive KRW 11 billion in funding	21-09-06	CI
WOOJUNG BIO, Inc. announced that it has received KRW 5 billion in funding	21-08-26	CI
WOOJUNG BIO, Inc. announced that it expects to receive KRW 5 billion in funding	21-08-24	CI
Chun Byung Nyun acquired an additional 6.4% stake in WOOJUNG BIO, Inc. for KRW 4.4 billion.	20-09-03	CI
WOOJUNG BIO, Inc. announced that it has received KRW 5.00000397 billion in funding	20-08-13	CI
WOOJUNG BIO, Inc. announced that it expects to receive KRW 5.00000397 billion in funding	20-07-30	CI
ByungNyun Chun, Chief Executive Officer of WOOJUNG BIO, Inc., acquired an additional stake in WOOJUNG BIO, Inc. for KRW 2 billion.	20-07-27	CI
Coronavirus infects Asia stocks with exposure to China	20-01-28	RE
ASX 200 : Coronavirus infects Asia stocks with exposure to China	20-01-28	RE
Tranche Update on WOOJUNG BIO, Inc.'s Equity Buyback Plan announced on November 15, 2017.	18-11-18	CI
WOOJUNG BIO, Inc.'s Equity Buyback announced on November 15, 2017 has expired with 789,780 shares, representing 3.74% for KRW 1,999.89 million.	18-11-13	CI
WOOJUNG BIO, Inc. announced that it has received KRW 2.5 billion in funding from Mirae Asset Daewoo Co., Ltd., Investment Arm, Focus Investment Co., Ltd.	18-08-09	CI
WOOJUNG BIO, Inc. announced that it has received KRW 10 billion in funding from a group of investors	18-08-09	CI
WOOJUNG BIO, Inc. announced that it expects to receive KRW 2.5 billion in funding from Mirae Asset Daewoo Co., Ltd., Investment Arm, Focus Investment Co., Ltd.	18-08-07	CI
WOOJUNG BIO, Inc. announced that it expects to receive KRW 10 billion in funding from a group of investors	18-08-07	CI
Woojung BSC, Inc. announces an Equity Buyback for KRW 2,000 million worth of its shares.	17-11-14	CI
Woojung BSC, Inc. authorizes a Buyback Plan.	17-11-14	CI
Focus Asset Management acquired 4.4% stake in Hanwha MGI Special Purpose Acquisition Co., Ltd..	17-04-24	CI
Woojung Bsc Inc. completed the acquisition of Hanwha MGI Special Purpose Acquisition CO., LTD. in a reverse merger transaction.	17-04-18	CI
Woojung Bsc Inc. entered into an agreement to acquire Hanwha MGI Special Purpose Acquisition CO., LTD. in a reverse merger transaction.	16-10-30	CI
SenzaGen Signs Distribution with Woojung Bsc	16-10-19	CI

Chart WOOJUNG BIO, Inc.

Duration

Period

More charts

Company Profile

Woojung Bio Inc is a Korea-based company principally engaged in the biological business. The Company operates its business through two segments. The Infection Control Business segment is engaged in the manufacture and sale of reagents, breeding equipment, hydrogen peroxide sterilizers and other products. The Biological Business segment is engaged in the provision of test agency, research service and passage management services.

Sector

Biotechnology & Medical Research

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
WOOJUNG BIO, INC.	-20.67%	16.69M
MODERNA, INC.	+25.69%	47.86B
LONZA GROUP AG	+46.90%	41.42B
IQVIA HOLDINGS INC.	-3.46%	40.66B
CELLTRION, INC.	-6.20%	28.92B
ICON PUBLIC LIMITED COMPANY	+9.17%	25.55B
ALNYLAM PHARMACEUTICALS, INC.	-20.42%	19.27B
BIO-TECHNE CORPORATION	+0.17%	12.15B
MEDPACE HOLDINGS, INC.	+28.07%	12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.24%	11.99B

Other Biotechnology & Medical Research